Side-by-side comparison of AI visibility scores, market position, and capabilities
Ivy League research university in Manhattan with 270+ year history; law, business, journalism, and medicine programs facing 2024 federal funding scrutiny over campus protest response.
Columbia University is a prestigious Ivy League research university located in Manhattan's Morningside Heights neighborhood, offering undergraduate, graduate, and professional education across arts and sciences, law (Columbia Law School), business (Columbia Business School), medicine (Vagelos College of Physicians and Surgeons), journalism (Columbia Journalism School), public health, social work, and engineering. Founded in 1754 as King's College by royal charter of King George II, Columbia is the fifth-oldest institution of higher education in the United States and generates approximately $6+ billion in annual revenue including research grants and clinical operations.\n\nColumbia's academic strengths include exceptional programs in neuroscience, biomedical engineering, public health, international affairs (SIPA - School of International and Public Affairs), finance and economics (Columbia Business School), and the arts. The university is located adjacent to Harlem in New York City, providing students with extraordinary access to New York's business, cultural, and media industries. Columbia's alumni include Barack Obama (undergraduate), Warren Buffett (Business School), and numerous Nobel laureates and heads of state.\n\nIn 2025, Columbia University faces several significant institutional challenges: the university became a center of the pro-Palestinian campus protest movement in spring 2024, with protest tent encampments and building occupations that led to police involvement and hundreds of arrests. The federal government under the Trump administration has scrutinized Columbia's response to antisemitism concerns, threatening federal funding cuts and ultimately resulting in federal funds freezes. These political pressures add to the institutional challenges Columbia shares with other elite universities including endowment management, faculty governance tensions, and navigating diversity and admissions policies post-SFFA Supreme Court ruling.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.